Jefferies analyst makes the case for Moderna after Pfizer and BioNTech rise on Covid-19 vaccine news

In this video

Share

Jefferies analyst makes the case for Moderna after Pfizer and BioNTech rise on Covid-19 vaccine news

Michael Yee, Jefferies health care and biotech analyst, joins 'Power Lunch' to discuss the news that Pfizer and BioNtech have announced a Covid-19 vaccine is more than 90 percent effective and what it means for biotech sector.
03:42
Mon, Nov 9 20202:38 PM EST